The anti-CD38 monoclonal antibody daratumumab is approved as a single agent for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) who received at least three prior lines of therapy, including proteasome inhibitor and immunomodulatory agent. A retrospective multicentric study was designed to evaluate feasibility, tolerability, and efficacy of daratumumab in monotherapy in RRMM.
Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey
Markovic, Uros;Romano, Alessandra;Bellofiore, Claudia;Bulla, Anna;Parisi, Marina Silvia;Mineo, Giuseppe;Poidomani, Massimo;Maugeri, Cinzia;Innao, Vanessa;Di Raimondo, Francesco;
2021-01-01
Abstract
The anti-CD38 monoclonal antibody daratumumab is approved as a single agent for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) who received at least three prior lines of therapy, including proteasome inhibitor and immunomodulatory agent. A retrospective multicentric study was designed to evaluate feasibility, tolerability, and efficacy of daratumumab in monotherapy in RRMM.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Daratumumab as Single Agent.pdf
accesso aperto
Tipologia:
Versione Editoriale (PDF)
Dimensione
1.41 MB
Formato
Adobe PDF
|
1.41 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
